[{"id":"5da85b32-a408-4a7c-97c0-1e46ceeee503","acronym":"","url":"https://clinicaltrials.gov/study/NCT05745623","created_at":"2023-02-27T15:01:07.171Z","updated_at":"2024-07-02T16:35:54.638Z","phase":"Phase 1/2","brief_title":"A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors","source_id_and_acronym":"NCT05745623","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zurletrectinib (ICP-723)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-02-27"}]